[Action of carminomycin on the kinetics of cell proliferation and some problems of its combined use with other cytostatic agents].
It was found autoradiographically that karminomycin in the therapeutic dose (0.7 mg/kg) significantly hindered cell proliferation of ascitic tumour L-1210, if the cells were at the stage of DNA proliferation during the drug administration. It was shown that karminomycin in a dose of 0.35 mg/kg administered intraperitoneally decreased the number of the leukemic cell of ascitic tumour P-388 by more than 2 times. Then the number of the leukemic cells increased and it doubled during 47 hours. Karminomycin in a dose of 0.7 mg/kg hindered leukemic cell proliferation during 120 hours. The effectiveness of karminomycin therapy in combination with phopurin or cyclophosphan depended on the treatment regimen. Potentiation of the antileukemic effect was noted in the simultaneus use of the drug or in the primary use of cerminomycin 2 hours before administration of phopurin or cyclophosphan. When phopurin or cyclophosphan was used 2 hours before administration of karminomycin, therapeutic effectiveness was lower.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use*; D001345:Autoradiography; D002360:Carubicin / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D008938:Mitosis / Q000187:drug effects; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D002360:Carubicin
Deĭstvie karminomitsina na kinetiku kletochnoĭ proliferatsii i nekotorye voprosy kombinirovannogo primeneniia ego s drugimi tsitostaticheskimi agentami.